PET agent unlocks door to Alzheimer's disease

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 32 No 9
Volume 32
Issue 9

A PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer's disease patients from those of healthy volunteers in a clinical trial at Johns Hopkins University.

A PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer's disease patients from those of healthy volunteers in a clinical trial at Johns Hopkins University.

Dr. Dean F. Wong, a professor of radiology and psychiatry at Johns Hopkins, and colleagues plugged F-18 into a compound known as florbetapir F-18, which is drawn to the beta-amyloid in Alzheimer's plaques. The compound has a half-life of about 110 minutes.

Testing the new compound in humans, Wong and his colleagues recruited 26 volunteers, 11 previously diagnosed with Alzheimer's disease and 15 healthy subjects of similar age who performed normally on cognitive tests. Each volunteer received a florbetapir PET scan, acquired over 90 minutes. The Alzheimer's patients showed significantly more of the agent in their brains than the healthy volunteers with the radiotracer accumulating in regions known to be associated with beta-amyloid deposits.

Recent Videos
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
Related Content
© 2025 MJH Life Sciences

All rights reserved.